Evaluating the Efficacy and Safety of Palopegteriparatide in Hypoparathyroidism from the PaTHway Trial

This episode, titled ‘Evaluating the Efficacy and Safety of Palopegteriparatide in Hypoparathyroidism from the PaTHway Trial,’ features panelists discussing the efficacy and safety data of palopegteriparatide in hypoparathyroidism from the phase 3 PaTHway trial as well as the limitations of the trial.

Led by the moderator, the expert endocrinologists examine the following critical questions:

1. Looking at the phase 3 PaTHway trial with palopegteriparatide in adults with chronic hypoparathyroidism, what stands out to you in terms of the efficacy and safety?
2. Which limitations of the study should clinicians keep in mind when interpreting these results?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, ‘Addressing Bone Health in the Management of Hypoparathyroidism’, panelists will continue their discussion on hypoparathyroidism and highlight strategies for managing patients with osteoporosis and hypoparathyroidism.